Drug profile · INN
articaine hydrochloride
ORABLOC
articaine hydrochloride (ORABLOC) is a sodium channel alpha subunit blocker. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — articaine hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
articaine hydrochloride (ORABLOC) is a sodium channel alpha subunit blocker. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is articaine hydrochloride?
articaine hydrochloride (ORABLOC) is a sodium channel alpha subunit blocker. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for articaine hydrochloride?
ORABLOC is a marketed brand name for articaine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of articaine hydrochloride?
articaine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.